Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Current Deferred Revenue (2021 - 2025)

BioNexus Gene Lab's Current Deferred Revenue history spans 5 years, with the latest figure at $8385.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $8385.0 for Q4 2025, down 91.25% from a year ago — trailing twelve months through Dec 2025 was $8385.0 (down 91.25% YoY), and the annual figure for FY2025 was $8385.0, down 91.25%.
  • Current Deferred Revenue for Q4 2025 was $8385.0 at BioNexus Gene Lab, down from $11264.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $95879.0 in Q4 2024 to a low of $5937.0 in Q2 2024.
  • The 5-year median for Current Deferred Revenue is $13335.0 (2023), against an average of $21806.2.
  • The sharpest move saw Current Deferred Revenue soared 177.85% in 2024, then plummeted 91.25% in 2025.
  • Year by year, Current Deferred Revenue stood at $30307.0 in 2021, then dropped by 23.7% to $23123.0 in 2022, then crashed by 64.46% to $8218.0 in 2023, then surged by 1066.7% to $95879.0 in 2024, then plummeted by 91.25% to $8385.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $8385.0, $11264.0, and $11348.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.